[Expression of VEGF, bFGF and ER in endometrial carcinoma].
OBJECTIVE
To investigate the expression of VEGF, bFGF and ER in endometrial carcinoma and its relation to the clinico-pathological manifestations and prognosis.


METHODS
A total of 66 specimens of endometrial carcinoma and 19 normal endometrium was studied by immunohistological technique with polyclonal antibodies against VEGF and bFGF, and monoclonal antibody against ER.


RESULTS
Positive expression rate of VEGF in endometrial carcinoma was 80.3%. Expression of VEGF was positively correlated with tumor grade (P < 0.01). Expression of VEGF was positively correlated with that of bFGF (P < 0.05). Negative correlation was observed between ER expression and tumor grade (P < 0.05). Prognosis of patients with negative ER expression was poor. No correlation existed between ER expression and that of VEGF and bFGF.


CONCLUSIONS
Expression of VEGF and bFGF may indicate that both of them contribute in the angiogenesis of endometrial carcinoma. Expression of ER has prognostic significance.
Bai
X
X
Gynecology and Obstetrics Department, General Hospital of Tianjin Medical University, Tianjin 300052, China.
Mi
R
R
D014408:Biomarkers, Tumor / Q000378:metabolism*; D018450:Disease Progression; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D016228:Endothelial Growth Factors / Q000378:metabolism*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D006801:Humans; D008222:Lymphokines / Q000378:metabolism*; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D014408:Biomarkers, Tumor; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011960:Receptors, Estrogen; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2